GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharma Q1 FY27 Standalone Profit Rs. 25333 Lakhs
RESULTS
● No Immediate Change
LOW RISK
📅 Filed on BSE: 03 Aug 2026, 03:43 PM IST · BSE ID: 0fe90a31-7069-4b4d-9c79-0f1b3cd6f589
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its latest quarterly financial results and announced changes to its board and management appointments.
🤖 AI Summary
- Standalone Profit for Q1 FY27 was Rs. 25333 Lakhs, with Revenue from operations at Rs. 92442 Lakhs.
- Consolidated Profit for Q1 FY27 was Rs. 23718 Lakhs, with Revenue from operations at Rs. 93844 Lakhs.
- Mr. Bhushan Akshikar re-appointed as Managing Director for two years, effective December 1, 2026.
- Ms. Karine J F Natland appointed as a Non-Executive Director to the Board, effective August 3, 2026 or DIN.
- Mr. Subesh Williams, Non-Executive Director, stepped down from the Board on August 3, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations (Q1 FY27)
92442 Rs. in Lakhs
14.86
Standalone Profit for the period (Q1 FY27)
25333 Rs. in Lakhs
23.76
Consolidated Revenue from operations (Q1 FY27)
93844 Rs. in Lakhs
16.55
Consolidated Profit for the period (Q1 FY27)
23718 Rs. in Lakhs
15.69
Standalone Basic & Diluted EPS (Q1 FY27)
14.95 Rs.
23.76
Consolidated Basic & Diluted EPS (Q1 FY27)
14.00 Rs.
15.70
🏢 How This Affects the Company
The company's standalone profit for Q1 FY27 was Rs. 25333 Lakhs and consolidated profit was Rs. 23718 Lakhs. Standalone revenue from operations for Q1 FY27 was Rs. 92442 Lakhs, while consolidated revenue was Rs. 93844 Lakhs.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance and changes in key management personnel and board composition. Mr. Bhushan Akshikar is re-appointed as Managing Director, and Ms. Karine J F Natland joins the board.
🔍
Management Signal
The re-appointment of Mr. Bhushan Akshikar indicates continuity in leadership, while the appointment of Ms. Karine J F Natland reflects an addition to board expertise.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor revenue and profit trends.
Subsequent board meeting outcomes — track further management or board changes.
Integration and contributions of new Non-Executive Director.
LOW RISK
The filing reports routine financial results and management changes without indicating new or elevated risks.
💡 Investor Takeaway
GlaxoSmithKline Pharmaceuticals reported standalone profit of Rs. 25333 Lakhs in Q1 FY27, up 23.76% YoY from Rs. 20470 Lakhs in Q1 FY26. Consolidated profit was Rs. 23718 Lakhs, an increase of 15.69% YoY from Rs. 20501 Lakhs. The Managing Director was re-appointed for two years.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Profit for Q1 FY27 increased to Rs. 25333 Lakhs, up from Rs. 20470 Lakhs in Q1 FY26.
- Consolidated Profit for Q1 FY27 increased to Rs. 23718 Lakhs, up from Rs. 20501 Lakhs in Q1 FY26.
⚠️ Concerns
- Standalone Revenue from operations for Q1 FY27 decreased to Rs. 92442 Lakhs from Rs. 98915 Lakhs in the preceding quarter.
- Consolidated Revenue from operations for Q1 FY27 decreased to Rs. 93844 Lakhs from Rs. 99530 Lakhs in the preceding quarter.
📅 Company Track Record
In FY26, GlaxoSmithKline Pharmaceuticals Ltd reported a Consolidated Profit of Rs. 103598 Lakhs and declared a Rs. 57 final dividend, as per filings on May 13, 2026. This Q1 FY27 filing continues the regular reporting of financial performance.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was GlaxoSmithKline Pharmaceuticals' standalone net profit for Q1 FY27?
GlaxoSmithKline Pharmaceuticals' standalone net profit for the quarter ended June 30, 2026 (Q1 FY27), was Rs. 25333 Lakhs.
What was GlaxoSmithKline Pharmaceuticals' consolidated revenue from operations in Q1 FY27?
The consolidated revenue from operations for GlaxoSmithKline Pharmaceuticals for the quarter ended June 30, 2026 (Q1 FY27), was Rs. 93844 Lakhs.
Who was re-appointed as Managing Director for GlaxoSmithKline Pharmaceuticals?
Mr. Bhushan Akshikar (DIN:09112346) was re-appointed as the Managing Director of GlaxoSmithKline Pharmaceuticals for a term of two years, effective December 1, 2026.
Who is the new Non-Executive Director appointed to the Board of GlaxoSmithKline Pharmaceuticals?
Ms. Karine J F Natland was appointed as a Non-Executive Director on the Board of GlaxoSmithKline Pharmaceuticals, effective from August 3, 2026, or upon obtaining her DIN, whichever is later.
How did standalone profit for GlaxoSmithKline Pharmaceuticals change year-over-year in Q1 FY27?
Standalone profit for GlaxoSmithKline Pharmaceuticals increased to Rs. 25333 Lakhs in Q1 FY27, up from Rs. 20470 Lakhs in the corresponding quarter ended June 30, 2025.
Questions based on this BSE filing only. For information purposes.